Length of travel appears to be associated with health risks.
Length of travel appears to be associated with health risks. GeoSentinel Surveillance Network data for 4,039 long-term travelers (trip duration >6 months) seen after travel during June 1, 1996, through December 31, 2008, were compared with data for 24,807 short-term travelers (trip duration <1 month). Long-term travelers traveled more often than short-term travelers for volunteer activities (39.7% vs. 7.0%) and business (25.2% vs. 13.8%). More long-term travelers were men (57.2% vs. 50.1%) and expatriates (54.0% vs. 8.9%); most had pretravel medical advice (70.3% vs. 48.9%). Per 1,000 travelers, long-term travelers more often experienced chronic diarrhea, giardiasis,
Travelers have many reasons for long durations of travel, including diplomatic work, education and research, missionary work, Peace Corps volunteer (PCV) work, military operations, backpacking trips, and corporate expatriate assignments (
To evaluate the effect of trip duration on illness, we compared illnesses by duration of travel for travelers seeking treatment at GeoSentinel Surveillance Network sites. We also characterized long-term travelers’ demographics, travel patterns, and travel-related illnesses.
GeoSentinel Surveillance Network (
Persons in our study must have crossed an international border within the past 10 years and then sought treatment or medical advice at a GeoSentinel site for a presumed travel-related illness. Only travelers with confirmed and probable diagnoses (including a healthy screening result) were included (
Flow chart for analysis of illness and injury in long-term travelers, GeoSentinel Surveillance Network, June 1996–December 2008.
Data were collected according to a standardized, anonymous questionnaire and entered into a Structured Query Language database. The questionnaire comprised demographic data (i.e., age, gender, country of birth, country of residence), travel history, inpatient or outpatient status, major diagnoses, pretravel encounter for travel health advice, reason for most recent travel, patient classification, and risk level qualifier (e.g., prearranged or organized travel, risk travel, and expatriate status). Included in the analysis were persons traveling for tourism, visits to friends and relatives (VFR), business, military purposes, education, research, or missionary/volunteer work. We excluded records lacking an exposure destination or duration of travel, as well as records of immigrating travelers, travelers with multiple trips without a specified location of exposure, final diagnoses attributed to travel of unspecified duration, travel duration of 1–6 months, and travelers seen during travel. We defined long-term travel as duration >6 months and short-term travel as duration <1 month. Data for specific diagnoses and syndromes were analyzed for travelers seen after travel.
Final diagnoses were assigned a diagnostic code from a standardized list of ≈500 diagnoses, which were categorized into 21 broad syndrome groups, as previously described (
Data were analyzed by using SAS software, version 9 (SAS Institute, Cary, NC, USA). Proportionate illness was calculated as the number of patients with a specific or grouped diagnosis as a proportion of short-term or long-term travelers, expressed per 1,000 persons in that category (
For long-term travelers, we performed multivariate logistic regressions to identify significant factors associated with various diseases. We adjusted for age, sex, pretravel encounters, reason for travel, and geographic region visited. Significant factors (p<0.05) were determined from stepwise selection.
Of 41,168 eligible persons seen after travel, 24,807 (60.3%) traveled for <1 month (short-term travelers), 12,322 (29.9%) traveled for 1–6 months, and 4,039 (9.8%) traveled for >6 months (long-term travelers). Mean ages were 33 years for long-term travelers and 38 for short-term travelers (
Long-term travelers more often traveled for volunteer activities or research (40% vs. 7%) and business (25% vs. 14%) and less often for tourism (29% vs. 70%). A larger proportion of long-term than short-term travelers were male (57% vs. 50%) and expatriates (54% vs. 9%), and most had sought pretravel medical advice (70% vs. 49%).
Long-term travelers more often traveled to sub-Saharan Africa (34%) and South America (16%) than did short-term travelers. Similar proportions of long- and short-term travelers went to south-central Asia (14% and 13%, respectively), and the proportion of long-term travelers with exposure in Southeast Asia was lower than that of short-term travelers. Intervals between return from travel to visit to a GeoSentinel site after long-term travel were <1 week (32%), 1–6 weeks (38%), and >6 weeks (30%).
Predominant syndromes in long-term travelers seen after travel were febrile systemic illness, acute diarrheal syndrome, dermatologic problems, and other gastrointestinal problems (
Proportions of common diagnoses in long-term travelers by world region visited are shown in
Proportionate illness (per 1,000 ill travelers) for the most frequent diagnoses in long-term travelers, by world geographic region visited, GeoSentinel Surveillance Network, June 1996–December 2008. PEP, postexposure prophylaxis; IBS, irritable bowel syndrome; TB, tuberculosis; LTBI, latent TB infection; CLM, cutaneous larva migrans;
| Rank† | Diagnosis | Rate/1,000 travelers | Odds ratio (95% confidence interval) | ||||
|---|---|---|---|---|---|---|---|
| Overall | South America | Southeast Asia | Sub-Saharan Africa | All other regions | |||
| 1 | Diarrhea, chronic unknown | 50 | 1.20‡ (1.04–1.38) | 1.19 (0.81–1.75) | 1.59§ (1.05–2.39) | 0.92 (0.64–1.31) | 1.19 (0.99–1.44) |
| 2 | 36 | 1.57‡ (1.32–1.86) | 0.85 (0.49–1.47) | 1.48 (0.80–2.73) | 1.93‡ (1.39–2.67) | 1.59‡ (1.26–2.01) | |
| 3 | Irritable bowel syndrome, postinfectious | 36 | 1.69‡ (1.41–2.01) | 2.13§ (1.42–3.18) | 2.76§ (1.52–5.02) | 1.59¶ (1.03–2.45) | 1.42§ (1.11–1.80) |
| 4 | Malaria, | 36 | 1.50‡ (1.26–1.78) | NA | 5.05‡ (2.58–9.88) | 1.05 (0.86–1.27) | 2.77§ (1.58–4.87) |
| 6 | Malaria, | 19 | 2.46‡ (1.92–3.17) | 0.83 (0.33–2.07) | 4.79‡ (2.86–8.01) | 1.14 (0.67–1.94) | 3.66‡ (2.57–5.22) |
| 8 | Fatigue >1 month (not febrile) | 18 | 3.09‡ (2.86–4.01) | 3.45§ (1.59–7.50) | 1.94 (0.86–4.37) | 1.79 (0.98–3.25) | 4.27‡ (3.01–6.05) |
| 9 | Eosinophilia | 17 | 3.34‡ (2.53–4.42) | 3.49§ (1.56–7.83) | 3.11§ (1.46–6.60) | 4.11‡ (2.46–6.84) | 2.89‡ (1.91–4.37) |
| 11 | Leishmaniasis, cutaneous | 14 | 4.89‡ (3.55–6.73) | 9.14‡ (5.15–16.24) | NA | 0.77 (0.09–6.40) | 2.30§ (1.35–3.92) |
| 12 | Schistosomiasis, human species unknown# | 13 | 4.45‡ (3.16–6.25) | 2.92 (0.18–46.68) | 3.30 (0.34–31.80) | 3.10‡ (2.09–4.59) | 7.44‡ (3.83–14.47) |
| 17 | TB, positive PPD or IGRA | 11 | 3.26‡ (2.33–4.56) | 2.92 (0.73–11.72) | 24.27‡ (8.52–69.17) | 2.44¶ (1.13–5.26) | 2.68‡ (1.71–4.18) |
| 18 | 11 | 3.33‡ (2.34–4.73) | 2.57 (0.93–7.10) | 1.52 (0.34–6.77) | 3.88‡ (1.95–7.72) | 3.52‡ (2.23–5.56) | |
| 21 | Stress | 9 | 5.70‡ (3.77–8.61) | NA | 1.65 (0.20–13.73) | 7.57‡ (3.13–18.30) | 5.55‡ (3.32–9.30) |
| 22 | Epstein-Barr virus | 8 | 2.60‡ (1.72–3.91) | 12.86‡ (3.65–45.27) | 2.99¶ (1.20–7.48) | 0.38 (0.05–2.96) | 2.29§ (1.30–4.03) |
| 25 | Strongyloidiasis, simple intestinal | 7 | 1.85§ (1.24–2.75) | 0.83 (0.17–4.01) | 3.11¶ (1.14–8.53) | 1.62 (0.88–2.99) | 1.89 (0.94–3.81) |
*Long-term travel is defined as >6 mo, short-term travel as <1 mo. NA, not applicable; TB, tuberculosis; PPD, purified protein derivative test; IGRA, interferon-gamma release assay.
†Among 25 most common illnesses for all travelers.
‡p<0.0001.
§p<0.01.
¶p<0.05.
#Aggregated schistosomiasis diagnoses (mansoni, haematobium, japonicum, mekongi, and unknown) are grouped together and shown in
Long-term travelers most commonly had diagnoses related to diseases with transmission by vectors or by ingestion. Larger proportions of long-term than short-term travelers had vector-borne diseases, contact-transmitted diseases (person-to-person, droplet, respiratory, sexually transmitted), and psychological problems (
| Grouped diagnoses | Rate/1,000 travelers | Odds ratio (95% CI) | |
|---|---|---|---|
| Short-term travelers | Long-term travelers | ||
| Vector-borne infections | 76 | 109 | 1.47 (1.33–1.63) |
| Dengue | 24 | 17 | 0.69 (0.551–0.88) |
| Chikungunya | 2 | 2 | 1.16 (0.59–2.29) |
| Leishmaniasis | 3 | 14 | 4.89 (3.55–6.73) |
| Malaria, all species | 39 | 68 | 1.83 (1.61–2.08) |
| Rickettsiosis | 8 | 2 | 0.22 (0.11–0.45) |
| Filariasis | 2 | 5 | 3.22 (1.981–5.24) |
| Ingestion | 257 | 219 | 0.81 (0.75–0.87) |
| Enteric fever | 5 | 9 | 1.70 (1.20–2.41) |
| Hepatitis A | 2 | 3 | 1.21 (0.67–2.19) |
| Diarrhea, acute | 123 | 41 | 0.31 (0.27–0.36) |
| Diarrhea, chronic | 45 | 54 | 1.20 (1.04–1.38) |
| GI bacteria | 34 | 15 | 0.42 (0.33–0.53) |
| Giardiasis | 24 | 36 | 1.57 (1.32–1.86) |
| GI parasites | 55 | 108 | 2.08 (1.88–2.312) |
| Contact‡ | 33 | 38 | 1.15 (0.70–1.90) |
| Influenza | 8 | 5 | 0.60 (0.39–0.92) |
| Latent TB (positive PPD or IGRAs) | 4 | 11 | 3.26 (2.33–4.56) |
| Acute mononucleosis syndrome (CMV, EBV, other) | 7 | 11 | 1.60 (1.18–2.18) |
| Hepatitis B | 2 | 2 | 0.67 (0.31–1.47) |
| Hepatitis C | 1 | 2 | 1.73 (0.85–3.49) |
| Other sexually transmitted infections | 7 | 4 | 0.67 (0.43–1.05) |
| HIV (acute infection) | 2 | 1 | 0.39 (0.12–1.27) |
| Environment | 119 | 87 | 0.71 (0.63–0.79) |
| Schistosomiasis | 6 | 24 | 4.26 (3.35–5.42) |
| Strongyloides | 4 | 7 | 1.85 (1.24–2.75) |
| Hookworm | 2 | 2 | 1.26 (0.62–2.60) |
| Animal bite | 44 | 13 | 0.28 (0.22–0.37) |
| Other skin contact, noninfectious | 60 | 18 | 0.29 (0.23–0.36) |
| Fungal infection (superficial/cutaneous mycosis) | 4 | 10 | 2.33 (1.66–3.28) |
| Rash | 19 | 19 | 0.98 (0.78–1.23) |
| Psychological | 15 | 40 | 2.80 (2.35–3.33) |
| Anxiety | 3 | 4 | 1.60 (0.96–2.65) |
| Depression | 2 | 6 | 3.03 (1.89–4.86) |
| Psychosis, nonmefloquine | 1 | 2 | 3.89 (1.68–8.99) |
| Stress | 2 | 9 | 5.70 (3.77–8.61) |
| Fatigue >1 mo | 6 | 18 | 3.09 (2.86–4.01) |
| Adverse events from medication or vaccine | 7 | 3 | 0.44 (0.26–0.74) |
| Mefloquine intolerance | 4 | 1 | 0.19 (0.07–0.52) |
| Medication intolerance, nonmefloquine | 3 | 2 | 0.83 (0.44–1.56) |
*Long-term travel defined as >6 mo, short-term as <1 mo. CI, confidence interval; GI, gastrointestinal; TB, tuberculosis; PPD, purified protein derivative; IGRA, interferon-gamma release assay; CMV, cytomegalovirus; EBV, Epstein-Barr virus.
†Diagnoses with proportionate illness <1/1,000 are omitted from table listing, such as hepatitis E, hepatitis delta, meningococcal meningitis,
Existing data are limited regarding the number and proportion of all long-term travelers. This analysis of the GeoSentinel Surveillance Network found that long-term travelers constituted 9.8% of all travelers visiting GeoSentinel sites. In comparison, 5 travel medicine clinics in the Boston area found that ≈5% of travelers planned trips of ≥4 months’ duration (
In our analysis, ingestion was the most common attributable route of transmission for diseases in long-term travelers, although long-term travelers sought treatment less frequently than short-term travelers for ingestion-transmitted diseases (OR 0.81, p<.0001). Enteric fever, acute diarrhea, chronic diarrhea, giardiasis, and other gastrointestinal parasites were reported significantly more often in long-term than short-term travelers (p = 0.0024 for enteric fever, p<0.0001 for the rest). Young age was associated with giardiasis and other gastrointestinal parasites, possibly because of inexperience or more risk-taking behavior. Giardiasis occured more often in long-term travelers to sub-Saharan Africa than in short-term travelers there (OR 1.93, p<.0001); that difference was not apparent for travelers to South America and Southeast Asia.
Epidemiologic surveillance of PCVs (1985–1987, >5,500 volunteers) found similar results: among the most common illnesses during service were diarrhea and giardiasis (
A major vaccine-preventable disease is typhoid fever. Long-term travelers more frequently had enteric fever (typhoid and paratyphoid) than did short-term travelers (9/1,000 vs. 5/1,000 travelers; OR 1.70, p = 0.0024). A past estimate of the attack rate for typhoid in expatriates was 3/100,000 travelers per month of stay (
A survey of corporate expatriates found that food safety practices worsened as duration of stay increased (
Long-term travelers more frequently had vector-borne diseases than did short-term travelers because of the longer period during which bites can occur and possibly less vigilance about personal protection measures and/or chemoprophylaxis during long stays. Long-term travelers also may have more primitive, remote, and rural living conditions than short-term travelers. Leishmaniasis, malaria, and filariasis were all reported more frequently in long-term travelers than in short-term travelers (14, 68, and 5/1,000 vs. 3, 39, and 2/1,000, respectively; p<0.0001). Regional variations were consistent with geographic disease distribution (
Seroprevalence studies confirm exposures to dengue virus in regions to which it is endemic: a serosurvey of 323 development workers and family members had increased seropositivity with longer stay (
Some psychological diagnoses were reported significantly more often in long-term travelers (OR 2.80, p<0.0001), particularly depression (OR 3.03, p<0.0001), nonmefloquine psychosis (OR 3.89, p = 0.0006), stress (OR 5.70, p<0.0001), and fatigue (OR 3.09, p<0.0001); rates of anxiety, insomnia, substance abuse, and posttraumatic stress disorder were equivalent to or lower than rates in short-term travelers. The increased number of missionary/volunteer/research/aid workers with stress was most significant (OR 32.18, (p<0.0001). Psychological rates were highest in eastern Europe and northern Africa and lowest in the Caribbean and Southeast Asia. Mission boards consider psychological conditions to be among the most common and serious conditions, specifically depression, stress, and burnout (
In a survey of 1,340 long-term travelers from Israel (mean stay 5.3 months), 151 (11.3%) had neuropsychiatric problems during travel with a higher proportion of women (54.6%) and an association with mefloquine use (
Although our analysis identified no substance abuse, an earlier study of 18–30-year-old travelers to the tropics found that approximately one third of survey responders used illicit drugs during their trip, especially travelers to the Far East. The strongest predictors of drug abuse were the combination of female sex and travel to Asia, education
Latent tuberculosis (positive purified protein derivative [PPD] or interferon-gamma release assays) was diagnosed more commonly in long-term than in short-term travelers (11 vs. 4/1,000; OR 3.26, p<0.0001), whereas influenza was diagnosed less commonly in long-term travelers (5 vs. 8/1,000, OR 0.60, p = 0.0183). PCVs serving in Madagascar most commonly reported respiratory problems and gastrointestinal and skin conditions, including 5.8% with Mantoux of
Acute mononucleosis syndromes was significantly higher in long-term than in short-term travelers (11 vs. 7/1,000 travelers, OR 1.60, p = 0.0024) but no significant difference for other diseases transmitted through sex or body fluids. Younger age, male sex, lack of pretravel advice, and exposure in western Europe were associated with diagnoses of acute mononucleosis syndromes.
Among PCVs in Madagascar, the reported incidence of sexually transmitted infections was 6.9% (5.6% of females and 13.3% of males); 8.7% of those volunteers needed postexposure prophylaxis for human immunodeficiency virus (
Among diagnoses attributed to soil and water exposure, schistosomiasis and strongyloidiasis were more common in long-term travelers (24 and 7/1,000 travelers; OR 4.26, p<0.0001, and 1.85, p = 0.0021, respectively) and were associated with males. Schistosomiasis was also associated with tourism and missionary/volunteer/research/aid work, and strongyloidiasis was associated with VFR. An earlier study found that 8 (11.6%) of 69 PCVs who served in Madagascar had antischistosomal antibodies (
Although ectoparasites (scabies, sand flea, and head lice) were reported in 11.6% of PCVs (
Rabies risk has been considered to increase with longer duration of travel, and preexposure prophylaxis is typically recommended, particularly for long stays. Our data showed a lower proportionate need for postexposure prophylaxis (not actual rabies) in long-term travelers than in short-term travelers (7 vs. 23/1,000, OR 0.31, p<0.0001), possibly because long-term travelers may be more knowledgeable or better educated about animal exposure risks, more likely to avoid exposures, and more likely to have been vaccinated before travel. In PCVs, potential exposure to rabies was 10× higher abroad than domestically (
Mission boards consider injury among the most common and serious conditions (
Our findings are subject to several limitations. The GeoSentinel database captures travelers who sought treatment at specialized travel and tropical medicine clinics and who may not be representative of all travelers. Long-term travelers may be more likely than short-term travelers to seek a GeoSentinel site because of concern about unusual tropical diseases. We used only GeoSentinel data, so proportionate frequency of diagnoses for long-term travelers compared with short-term travelers in this database can be derived, but not risk for illness. Missing travel duration eliminated ≈10% of records from analysis. Paucity of injury data is another limitation of the analysis because injury is a major cause of illness and death in long-term travelers. Similarly, travelers with dental, ophthalmologic, obstetric, and gynecologic problems rarely visit GeoSentinel sites.
Approximately 10% of all ill travelers seen at GeoSentinel sites are long-term travelers. Long-term travelers are characterized by male gender and travel for missionary/volunteer/research or business; most had pretravel evaluations. Among the problems more frequently seen in long-term travelers than in short-term travelers are infections with long incubation and long-lasting or chronic durations; malaria is especially important, as are leishmaniasis, filariasis, gastrointestinal parasites, schistosomiasis, and latent tuberculosis. Many vector-borne diseases with short incubation periods (e.g., dengue, chikungunya, rickettsia) are diagnosed more often in short-term travelers. These findings do not mean that these infections occur less often in long-term travelers, only that they are not active when long-term travelers are seen after travel; a similar situation may be true for animal bites. Many common infections seen in long-term travelers are preventable by vaccines, vector avoidance, food/water precautions, and avoidance of soil and fresh water. Psychological problems, especially depression, stress, nonmefloquine psychosis, and prolonged fatigue, increase with long-term travel. The high OR (32.18) of missionary/volunteer/research/aid workers with stress merits attention and intervention. Clinicians must be alert to psychological problems and manage them, as reentry and readjustment for long-term travelers may be difficult. Among the vaccine-preventable diseases, enteric fever and hepatitis A increase with long-term travel. Because >50% of ailments for which long-term travelers visit a healthcare provider are preventable and 70% of long-term travelers had pretravel visits, opportunities exist to educate, vaccinate, provide malaria chemoprophylaxis, and prepare these travelers for possible break-through infection.
Disease patterns differed significantly for long-term and short-term travelers. Particular areas of concern for long-term travelers are vector-borne, ingestion-transmitted, contact-transmitted disease, and psychological problems. Our results can help identify priorities for screening and diagnosing illnesses in long-term travelers and for providing evidence-based pretravel advice.
GeoSentinel Surveillance Network demographics of long-term and short-term travelers (N = 28,846), June 1996-December 2008*
Frequency of diagnoses by syndrome groups in long-term and short-term travelers (N = 33,360), GeoSentinel Surveillance Network, June 1996-December 2008*
Summary table of logistic regression performed on long-term travelers seen after travel showing significant variables associated with common diagnoses, GeoSentinel Surveillance Network, June 1996-December 2008*
1The following members of the GeoSentinel Surveillance Network also contributed data (in descending order): Frank von Sonnenburg, University of Munich, Munich, Germany; Stefanie S. Gelman, University of Utah, Salt Lake City, Utah, USA; François Chappuis, University of Geneva, Geneva, Switzerland; Kevin C. Kain, University of Toronto, Toronto, Canada; Vanessa Field, InterHealth, London, UK; Gerd-Dieter Burchard, Bernhard–Nocht Institute for Tropical Medicine, Hamburg, Germany; Michael D. Libman and J. Dick Maclean, McGill University, Montreal, Quebec, Canada; Karin Leder, Joseph Torresi, and Graham Brown, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Philippe Parola, Fabrice Simon, and Jean Delmont, Hôpital Nord, Marseille, France; Robert Kass, Travellers Medical and Vaccination Centres of Australia, Adelaide, South Australia, Australia (December 1997–March 2001 only); Giampiero Carosi and Francesco Castelli, University of Brescia, Brescia, Italy; Prativa Pandey, CIWEC Clinic Travel Medicine Center, Kathmandu, Nepal; Marc Shaw, Worldwise Travellers Health and Vaccination Centre, Auckland, New Zealand; Phyllis E. Kozarsky and Carlos Franco-Paredes, Emory University, Atlanta, Georgia, USA; Watcharapong Piyaphanee and Udomsak Silachamroon, Mahidol University, Bangkok, Thailand; Natsuo Tachikawa and Hiroko Sagara, Yokohama Municipal Citizen's Hospital, Yokohama, Japan; Bradley A. Connor, Cornell University, New York City, New York, USA; Shuzo Kanagawa and Yasuyuki Kato, International Medical Center of Japan, Tokyo, Japan; Mogens Jensenius, Ullevål University Hospital, Oslo, Norway; N. Jean Haulman, David Roesel, and Elaine C. Jong, University of Washington, Seattle, Washington, USA; Christina M. Coyle and Murray Wittner, Albert Einstein School of Medicine, Bronx, New York, USA; Rogelio López-Vélez and Jose Antonio Pérez-Molina, Hospital Ramon y Cajal, Madrid, Spain; Thomas B. Nutman and Amy D. Klion, National Institutes of Health, Bethesda, Maryland, USA; Stefan Hagmann and Andy Miller, Bronx–Lebanon Hospital Center, Bronx; Rainer Weber and Robert Steffen, University of Zürich, Zürich, Switzerland; William M. Stauffer and Patricia F. Walker, University of Minnesota, Minneapolis, Minnesota, USA; David O. Freedman, University of Alabama at Birmingham, Birmingham, Alabama, USA; Vernon Ansdell, Kaiser Permanente, Honolulu, Hawaii, USA (October 1997–January 2003 only); Annelies Wilder-Smith, Tan Tock Seng Hospital, Singapore; R. Bradley Sack and Robin McKenzie, Johns Hopkins University, Baltimore, Maryland, USA (December 1997–August 2007 only); Eric Caumes and Alice Pérignon, Hôpital Pitié-Salpêtrière, Paris, France; Carmelo Licitra and Antonio Crespo, Orlando Regional Health Center, Orlando, Florida, USA; Elizabeth D. Barnett, Boston University, Boston, Massachusetts, USA; Alejandra Gurtman, Mount Sinai Medical Center, New York City (October 2002– August 2005 only); Cecilia Perret and Francisca Valdivieso, Pontificia Universidad Católica de Chile, Santiago, Chile; Robert Muller, Travel Clinic Services, Johannesburg, South Africa (May 2004–June 2005 only); John D. Cahill and George McKinley, St Luke’s–Roosevelt Hospital Center, New York City; Susan McLellan, Tulane University, New Orleans, Louisiana, USA (December 1999–August 2005 only); Susan MacDonald, Beijing United Family Hospital and Clinics, Beijing, Peoples Republic of China; Michael W. Lynch, Fresno International Travel Medical Center, Fresno, California, USA; Sarah Borwein, TravelSafe Medical Centre, Hong Kong Special Administrative Region, China; and Anne Anglim, University of Southern California, Los Angeles, California, USA.
We thank Elena Axelrod and Adam Plier for their technical and organizational support, Hanspeter Jauss for graphics assistance, and the GeoSentinel sites for providing data.
GeoSentinel, the Global Surveillance Network of the International Society of Travel Medicine, is supported by Cooperative Agreement U50/CCU412347 from the US Centers for Disease Control and Prevention. The Cambridge, UK, site is funded by the Biomedical Research Centre through the National Institute for Health Research (NIHR) Biomedical Research Centre for GeoSentinel activities.
Dr Chen directs the Travel Medicine Center at Mount Auburn Hospital and is assistant clinical professor at Harvard Medical School. Her clinical interests include malaria, dengue, travelers’ health, and travel-associated emerging infections.